Year-end Sale % OFF 
Abstract
BackgroundThe inability of Mycobacterium leprae to grow on axenic media has necessitated specialized techniques in order to determine viability of this organism. The purpose of this study was to develop a simple and sensitive molecular assay for determining M. leprae viability directly from infected tissues.Methodology/Principle FindingsTwo M. leprae-specific quantitative reverse transcription PCR (qRT-PCR) assays based on the expression levels of esxA, encoding the ESAT-6 protein, and hsp18, encoding the heat shock 18 kDa protein, were developed and tested using infected footpad (FP) tissues of both immunocompetent and immunocompromised (athymic nu/nu) mice. In addition, the ability of these assays to detect the effects of anti-leprosy drug treatment on M. leprae viability was determined using rifampin and rifapentine, each at 10 mg/kg for 1, 5, or 20 daily doses, in the athymic nu/nu FP model. Molecular enumeration (RLEP PCR) and viability determinations (qRT-PCR) were performed via Taqman methodology on DNA and RNA, respectively, purified from ethanol-fixed FP tissue and compared with conventional enumeration (microscopic counting of acid fast bacilli) and viability assays (radiorespirometry, viability staining) which utilized bacilli freshly harvested from the contralateral FP. Both molecular and conventional assays demonstrated growth and high viability of M. leprae in nu/nu FPs over a 4 month infection period. In contrast, viability was markedly decreased by 8 weeks in immunocompetent mice. Rifapentine significantly reduced bacterial viability after 5 treatments, whereas rifampin required up to 20 treatments for the same efficacy. Neither drug was effective after a single treatment. In addition, host gene expression was monitored with the same RNA preparations.Conclusions hsp18 and esxA qRT-PCR are sensitive molecular indicators, reliably detecting viability of M. leprae in tissues without the need for bacterial isolation or immediate processing, making these assays applicable for in vivo drug screening and promising for clinical and field applications.
Highlights
Mycobacterium leprae, an obligate intracellular pathogen and the etiologic agent of leprosy, cannot be grown in axenic medium
acid fast bacilli (AFB) counts and RLEP PCR yield viability information only indirectly, as bacterial numbers increase over time in a growing population
We developed two M. lepraespecific quantitative reverse transcription PCR assays and tested their utility as biological markers of M. leprae viability in tissue specimens
Summary
Mycobacterium leprae, an obligate intracellular pathogen and the etiologic agent of leprosy, cannot be grown in axenic medium. Limited growth occurs in the footpads (FPs) of conventional mice [1,2], whereas more prolific growth is attained in immunosuppressed rodents [3,4,5,6] and armadillos [7] In these models bacterial multiplication is measured in terms of months to years. Microscopic counting of acid fast bacilli (AFB) is used to enumerate M. leprae [2,8,9] This method is considered the gold standard, it is time consuming, labor intensive and restricted with regard to specificity. RLEP PCR had correlative results with microscopic counting and allowed for rapid and specific quantification of M. leprae from both mouse and armadillo tissues. The purpose of this study was to develop a simple and sensitive molecular assay for determining M. leprae viability directly from infected tissues
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
